» Articles » PMID: 35796622

RNA Helicase DEAD-box Protein 5 Alleviates Nonalcoholic Steatohepatitis Progression Via Tethering TSC Complex and Suppressing MTORC1 Signaling

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2022 Jul 7
PMID 35796622
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Nonalcoholic fatty liver disease and its progressive form, nonalcoholic steatohepatitis (NASH), are rapidly becoming the top causes of hepatocellular carcinoma (HCC). Currently, there are no approved therapies for the treatment of NASH. DEAD-box protein 5 (DDX5) plays important roles in different cellular processes. However, the precise role of DDX5 in NASH remains unclear.

Approach And Results: DDX5 expression was downregulated in patients with NASH, mouse models with diet-induced NASH (high-fat diet [HFD], methionine- and choline-deficient diet, and choline-deficient HFD), mouse models with NASH-HCC (diethylnitrosamine with HFD), and palmitic acid-stimulated hepatocytes. Adeno-associated virus-mediated DDX5 overexpression ameliorates hepatic steatosis and inflammation, whereas its deletion worsens such pathology. The untargeted metabolomics analysis was carried out to investigate the mechanism of DDX5 in NASH and NASH-HCC, which suggested the regulatory effect of DDX5 on lipid metabolism. DDX5 inhibits mechanistic target of rapamycin complex 1 (mTORC1) activation by recruiting the tuberous sclerosis complex (TSC)1/2 complex to mTORC1, thus improving lipid metabolism and attenuating the NACHT-, leucine-rich-repeat (LRR)-, and pyrin domain (PYD)-containing protein 3  inflammasome activation. We further identified that the phytochemical compound hyperforcinol K directly interacted with DDX5 and prevented its ubiquitinated degradation mediated by ubiquitin ligase (E3) tripartite motif protein 5, thereby significantly reducing lipid accumulation and inflammation in a NASH mouse model.

Conclusions: These findings provide mechanistic insight into the role of DDX5 in mTORC1 regulation and NASH progression, as well as suggest a number of targets and a promising lead compound for therapeutic interventions against NASH.

Citing Articles

Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review.

Deng Y, Dong Y, Zhang S, Feng Y Front Pharmacol. 2024; 15:1463187.

PMID: 39290869 PMC: 11405192. DOI: 10.3389/fphar.2024.1463187.


DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression.

Li Z, Kim W, Utturkar S, Yan B, Lanman N, Elzey B Cell Death Dis. 2024; 15(8):583.

PMID: 39122708 PMC: 11315975. DOI: 10.1038/s41419-024-06977-z.


Prevalence of Liver Steatosis in Tuberous Sclerosis Complex Patients: A Retrospective Cross-Sectional Study.

De Bock T, Brussaard C, Francois S, Francois K, Seynaeve L, Jansen A J Clin Med. 2024; 13(10).

PMID: 38792433 PMC: 11122077. DOI: 10.3390/jcm13102888.


Genome-wide characterization of circulating metabolic biomarkers.

Karjalainen M, Karthikeyan S, Oliver-Williams C, Sliz E, Allara E, Fung W Nature. 2024; 628(8006):130-138.

PMID: 38448586 PMC: 10990933. DOI: 10.1038/s41586-024-07148-y.


Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis.

Wang Y, Yu H, Cen Z, Zhu Y, Wu W Metabol Open. 2024; 21:100267.

PMID: 38187470 PMC: 10770762. DOI: 10.1016/j.metop.2023.100267.